# GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF")
Canonical URL: https://biopharmsignal.com/news/GRI/gri-bio-s-gri-0621-demonstrates-encouraging-safety-results-at-planned-interim-6-week-analysis-in-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis-ipf
Ticker: GRI
Company: GRI Bio
Source: GRI Bio
Published: 2025-06-26 08:00 EST
Original Source URL: https://www.pressviewer.com
## Summary

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="center"><em>The Independent Data Monitoring Committee ("IDMC") has recommended to continue the study as planned as there are no safety concerns demonstrated in the data reviewed</e

## Article Body
The Independent Data Monitoring Committee ("IDMC") has recommended to continue the study as planned as there are no safety concerns demonstrated in the data reviewed

Interim results to date demonstrate GRI-0621 to be safe and well-tolerated in the first 24 patients evaluated

6-week...
## Recent Company News
- 2026-06-18 13:31 EST — [GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis](https://biopharmsignal.com/news/GRI/gri-bio-secures-fda-orphan-drug-designation-for-gri-0621-tazarotene-in-idiopathi-36c7f058) — Source: GRI Bio
- 2026-05-14 08:35 EST — [GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline](https://biopharmsignal.com/news/GRI/gri-bio-reports-first-quarter-2026-financial-results-new-data-reinforcing-differentiated-profile-of-gri-0621-in-idiopathic-pulmonary-fibrosis-and-highlights-continued-advancement-of-differentiated-immune-modulating-pipeline) — Source: GRI Bio
- 2026-04-08 08:30 EST — [GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions](https://biopharmsignal.com/news/GRI/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions) — Source: GRI Bio
- 2026-02-17 09:15 EST — [GRI Bio CEO, Marc Hertz, Featured in Virtual Investor "What This Means" Segment](https://biopharmsignal.com/news/GRI/gri-bio-ceo-marc-hertz-featured-in-virtual-investor-what-this-means-segment) — Source: GRI Bio
- 2026-02-05 09:15 EST — [GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial](https://biopharmsignal.com/news/GRI/gri-bio-to-participate-in-the-corporate-connect-webinar-series-virtual-conference-hosted-by-webull-financial) — Source: GRI Bio
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)